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Abstract 
Hepatitis C virus (HCV) infection is one of the main 
causes of chronic liver disease and hepatocellular 
carcinoma worldwide and is an important public health 
concern. A retrospective analysis of the demographics and 
management of patients who had a positive anti-HCV 
detected by enzyme immunoassay test done at Mater Dei 
Hospital was carried out to analyse the epidemiology of 
HCV infection in Malta and assess our management when 
compared to the European Association for the Study of 
the Liver (EASL) guidelines. 72% of patients were male. 
The majority of patients were aged 21-50 years. The main 
mode of infection was via intravenous drugs use, 
accounting for 68% of cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only 56% of patients found to be HCV Ab positive 
had a scheduled appointment with an infectious diseases 
specialist or gastroenterologist documented on the MDH 
online appointment system. 58% of patients had HCV 
RNA testing done and 45% had genotype testing. 7.3% 
with HCV infection were given treatment, of which 43% 
had a Sustained Virological Response (SVR). 
 
Keywords  
Hepatitis C virus, EASL guidelines, management, 
treatment  
 
Introduction  
The Management of Patients Positive to Hepatitis C 
Virus Antibody in MaltaHepatitis C virus (HCV) infection 
is one of the main causes of chronic liver disease 
worldwide.1 WHO estimates that about 150 million people 
are chronically infected with HCV and that every year 
more than 350 000 people die from HCV-related liver 
diseases.2 
HCV is a single-stranded enveloped RNA virus 
belonging to the Flaviviridae family. The outcome of 
HCV infection on the liver may range from minimal 
changes to acute or chronic hepatitis, cirrhosis and 
hepatocellular carcinoma. 75-85% of patients infected 
with HCV will not clear the virus by 6 months, thus 
developing chronic HCV infection. Cirrhosis develops in 
approximately 10- 15% of individuals with chronic HCV 
infection over twenty years.3 The European Association 
for the Study of the Liver (EASL) has issued guidelines 
on the management of patients infected with HCV. In this 
study we have audited the management of chronic HCV 
with respect to the EASL guidelines.  
 
Method 
The audit is a retrospective analysis of the demographics 
and management of patients who had a positive HCV Antibody 
detected by EIA test done at the Virology Laboratory at Mater 
Dei Hospital. The time period studied was between January 
2008 and May 2012, during which there were a total of 1,074 
unique positive tests. Of these, 538 patients could not be 
identified as the tests were coded and 25 patients never had a 
file created or their file was misplaced. The remaining 506 files 
were viewed at medical records. This is a limiting factor of the 
study since not all the files could be traced. The following data pertains to 
these 506 patients. 
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Results 
Demographics 
 72% (363) of patients were male. The age 
distribution of the patients with a positive HCV antibody 
test is shown in Graph 1. 77.7% of patients who tested 
positive were aged 21-50 years. This model of infection 
suggests that the risk for HCV infection was greatest in 
the relatively recent past and primarily affects young 
adults. Table 1 describes the nationality of individuals 
with a positive HCV antibody test, with 81% of patients 
being Maltese. 
 
Figure 1: Age distribution of patients 
 
 
Table 1: Nationality of individuals with a positive HCV 
antibody test 
Nationality Percentage 
Maltese 81% 
African & Eastern countries 11% 
West Europe 6% 
Other 2% 
 
 The residing locality of the patients was documented 
to analyze the distribution of HCV in Malta. The 
population estimate for each locality was obtained from 
The Malta Government Gazette (Number 18,789 
published on Tuesday 9th August, 2011).4 The number of 
patients infected with HCV living in a particular locality 
was multiplied by 106 and divided by the population living 
in that location thus allowing us to compare localities 
(Table2).  
 
 The highest ranking localities are mainly Harbour or 
Inner Harbour areas or localities associated with 
recreation. 
Table 2: Highest Ranking Relative Prevalence Rates 
according to localities 
 
Mode of Infection 
Chart 1 shows the alleged mode of infection. 68% of 
patients were known IVDU. In 2% of cases, the alleged 
mode of infection was via blood transfusions infected with 
HCV prior to the introduction of blood screening. In these 
cases, blood transfusions were the only risk factor 
documented in the notes. Vertical and sexual transmission 
accounted for 1% each whilst there was only one case 
(0.2%) of a needle stick injury resulting in infection. In 
27% of cases, no risk factors were documented. 
 
Investigations 
 Diagnosis of ongoing HCV infection requires the 
presence of HCV RNA, which is detected by molecular 
assays such as PCR. In our study, only 58% of patients 
had HCV RNA checked with 46% being positive and 11% 
negative. A negative HCV RNA in a patient who has a 
positive HCV Ab could be due to previous successful 
treatment, neonates who received the HCV Ab via 
transplacental transfer of the antibody, spontaneous 
clearance of the virus, a low viral load that is below the 
limit of detection of the laboratory or a false positive HCV 
Ab. 
HCV is divided into six genotypes with numerous 
subtypes. Genotype 1, with subtypes 1a and 1b is the most 
prevalent genotype worldwide. Genotype 3a is highly 
prevalent among European IVDU5 whilst genotype 1b is 
associated with blood transfusions.6 In our study, it was 
shown that genotype testing was done in 20.5% of 
patients, with genotype 1a accounting for 45% of cases. 
(Chart 2). HCV genotype testing should be assessed in 
patients prior to starting antiviral therapy as it is important 
to decide treatment duration and dose of ribavirin.  
 
Rank Locality 
No. of 
people 
with HCV 
in the 
locality 
Population4 
Relative 
Prevalence 
No./Populati
on 
X106 
1 COSPICUA 30 5658 530 
2 VALLETTA 23 6966 330 
3 ST.VENERA 18 6939 259 
4 FLORIANA 5 2335 214 
5 ST.JULIANS 22 10573 208 
6 HAMRUN 18 9649 187 
7 VITTORIOSA 5 2758 181 
8 GZIRA 15 8392 178 
9 MSIDA 16 9227 173 
10 KALKARA 5 2999 167 
  
 
 
 
Original Article   
 
 
  
Malta Medical Journal    Volume 25 Issue 04 2013                                                                                                                 
 
75 
Figure 2: Alleged mode of Infection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Distribution of Genotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
EASL guidelines recommend that assessment of 
liver disease should include alanine aminotransferase, 
aspartate aminotransferase, gamma-glutamyl 
transpeptidase, alkaline phosphatase, bilirubin, INR, 
albumin, gammaglobulins, full blood counts and an 
abdominal ultrasound.1 Having low platelet counts, high 
INR, low albumin and high bilirubin is highly suggestive 
of underlying cirrhosis. (Table 3) 
 
 
Table 3: Blood Tests 
Value 
Percentage of 
patients 
Number of 
patients tested 
Platelets  
< 150 x109/L 
21% n=499 
INR > 1.3 10.5% n=416 
Albumin   
< 35g/dL 
14.5% n=343 
Bilirubin  
> 30µmol/L 
10% n=454 
 
An ultrasound was done in 51% of patients. The 
finding of a nodular liver (suggestive of liver cirrhosis) 
was present in 9%. Ascites, which is indicative of liver 
failure, was found in 9%. Splenomegaly (suggestive of 
portal hypertension) was found in 18%. 
HCV infection is associated with a 15 to 20-fold 
increase in hepatocellular carcinoma (HCC). The rate of 
HCC among patients with HCV infection ranges from 1- 
3% over 30 years.7 In our study, HCC was found in 4% of 
patients who underwent an US abdomen, 80% of who 
were male. 
A liver biopsy is done locally to assess the severity 
of liver disease, unless the patient is already has 
established liver cirrhosis. EASL guidelines state that a 
liver biopsy is regarded as the reference method to assess 
the degree of inflammation and fibrosis.1 A standardized 
scoring system is used to report the grade, which is the 
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degree of inflammation and stage, which is the degree of 
fibrosis. Both values range from 0 being no inflammation 
or fibrosis, progressively worsening with a higher grade or 
stage until 4 is severe inflammation or fibrosis (termed 
liver cirrhosis). Assessment of the severity of hepatic 
disease is important in decision making with regards to 
treatment as patients with cirrhosis are less likely to 
respond to therapy and have a worse prognosis post-
treatment1. In this study, 47 patients (9%) underwent a 
liver biopsy (Charts 3 and 4). 80% of patients have either 
no, minimal or mild inflammation and fibrosis which a 
good prognostic factor for treatment. Alternative non-
invasive methods such as transient elastography can also 
be used to assess liver fibrosis in patients with chronic 
HCV1; however this non-invasive test is not available 
locally. 
 
Figure 4: Distribution of Grade of liver biopsies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Distribution of the Stage of liver biopsies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referrals 
56% of patients found to be HCV Ab positive had a 
scheduled appointment with an infectious diseases 
specialist or gastroenterologist documented on the MDH 
online appointment system.  
 
 
Treatment 
Prior to the introduction of combination therapy, 
monotherapy with alpha interferon (IFN) was used. When 
combination therapy of pegylated interferon IFN-α (PEG 
IFN) and ribavirin was introduced, it became the standard 
treatment. Single therapy is nowadays only used if the 
patient cannot tolerate dual therapy due to side-effects.  
37 out of the 506 patients audited (7.3%) were treated 
with either both PEG IFN and ribavirin or else with IFN 
alone. 55 patients (10.9%) were HCV RNA negative, and 
therefore treatment was not needed whilst 44 patients 
(8.7%) were in liver cirrhosis, so treatment was not given 
due to the risk of decompensation. 24 patients had an 
uncontrolled psychiatric condition and thus treatment was 
contraindicated. Chart 5 describes all patients who were 
deemed ineligible for treatment. 
 
Figure 6: Ineligibility for treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sustained virological response (SVR) is defined as an 
undetectable HCV RNA level (<50 IU/mL) 24 weeks after 
cessation of treatment. Null response is defined as failure 
to achieve a decline of 2 logs HCV RNA IU/mL after 12 
weeks of treatment or failure to achieve undetectable 
HCV RNA during treatment of a minimum duration of 24 
weeks. Relapse is defined as having achieved undetectable 
HCV RNA at the end of treatment but HCV RNA is 
detected after stopping treatment1. 
Out of the 37 patients who were treated with either 
PEG IFN and ribavirin or IFN alone, 43% went into SVR, 
8% were Null responders, 8% relapsed, 8% were lost to 
follow-up and 11% had to stop treatment due to side-
effects (Chart 6). 
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Figure 7: Response to Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
HCV is one of the leading causes of liver disease, 
cirrhosis and HCC and one of the most common 
indications for liver transplantation.3 It is estimated that 
the prevalence of HCV infection is approximately 2.2-3% 
worldwide.9  
Presently the main mode of transmission of HCV is 
via sharing of devices used for illegal drug use. These 
include both IVDU and nasal drug use. Measures have 
been instituted to attempt to decrease the risk of HCV 
transmission by providing free new syringes from health 
centres. It is of utmost importance to draw attention of the 
risks of sharing needles and apparatus to drug users at 
every visit and to educate the general public via national 
education campaigns. This study indicated the highest 
ranking localities where patients resided and these areas 
should be particularly targeted.  
Some of the reasons for shortcomings in HCV 
management in Malta are due to the fact that the patient 
population can be difficult to work with as most patients 
are IVDU and there is stigma associated with both drug 
use and HCV infection. The disease is also clinically 
silent and so patients will present late unless the infection 
is picked up by screening blood tests. Inadequate referrals 
to appropriate specialists may occur because of lack of 
awareness amongst doctors of the rapid advances in 
management of HCV over the past years and the current 
success rates. Patients should also be encouraged by their 
GPs to attend Outpatients appointments and undergo the 
necessary investigations. In order to receive treatment 
patients frequently depend on funding from NGOs since 
the medications are not available on the NHS and are 
relatively expensive. This might also partly account of the 
small percentage of patients who were treated.  
Once a patient is then referred to the appropriate 
specialist, the management is then of high standards and 
success rates are good. In clinical trials, SVR was 
achieved in 40-54% of patients infected with HCV 
genotype 1 who were given PEG IFN and ribavirin 
combination therapy and in 65-82% of patients infected 
with genotype 2 or 3.1 SVR rates with monotherapy are 
lower. In the study population, 43% of patients (all 
genotypes included) went into SVR when treated with 
either combination therapy or IFN alone. IFN was used 
prior to the introduction of combination therapy. Thus, 
especially taking into account that both monotherapy and 
combination therapy are included, SVR rates for patients 
with HCV in Malta are favourable when compared to 
SVR rates in clinical trials. 
Trials have shown that relapse rate after treatment 
with combination therapy varies between 15-25%.1 In our 
study, 8% of patients relapsed on either monotherapy or 
combination therapy. In clinical trials, 32-53% of patients 
who relapsed after being given IFN alone then responded 
to combination therapy with PEG IFN and ribavirin.1 
Thus, patients who relapsed should be reassessed with an 
aim to give combination therapy.  
4-14% of treated patients will not respond to 
combination therapy.1 In our study population, 8% of 
patients treated with monotherapy or combination therapy 
were non-responders.  
Recent studies have shown that boceprevir or 
telaprevir in combination with PEG IFN and ribavirin 
(triple therapy) result in substantially higher sustained 
virological response rates in both treatment-naïve as well 
as in previous non responders with genotype 1 HCV 
chronic hepatitis. Triple therapy is however associated 
with increased side effects, increased drug interactions, 
increased cost and reduced cost effectiveness.8 
 This article highlights the need to refer all patients with 
positive HCV antibody tests to a gastroenterologist or an 
infectious disease physician for assessment of hepatic 
function and suitability for treatment. Management of 
these patients at Mater Dei Hospital mirrors the results 
obtained from international studies and therefore this 
treatment offers the best hope of a cure for these patients. 
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